USANA Health Sciences (NYSE:USNA) Releases Q3 2021 Earnings Guidance

USANA Health Sciences (NYSE:USNA) updated its third quarter 2021 earnings guidance on Thursday. The company provided EPS guidance of $1.280-$1.330 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.440. The company issued revenue guidance of $265 million-$270 million, compared to the consensus revenue estimate of $303.24 million.USANA Health Sciences also updated its FY 2021 guidance to $5.800-$6.000 EPS.

USNA has been the subject of several recent analyst reports. Zacks Investment Research upgraded shares of USANA Health Sciences from a sell rating to a hold rating in a research report on Wednesday, September 29th. Tigress Financial reaffirmed a buy rating and set a $122.00 price objective on shares of USANA Health Sciences in a research report on Friday, October 8th.

USNA traded up $0.21 during midday trading on Thursday, reaching $97.39. 100 shares of the company’s stock were exchanged, compared to its average volume of 88,851. USANA Health Sciences has a 1-year low of $73.00 and a 1-year high of $107.85. The business’s 50-day moving average price is $94.42 and its 200 day moving average price is $98.19. The stock has a market capitalization of $1.95 billion, a PE ratio of 14.66 and a beta of 0.85.

USANA Health Sciences (NYSE:USNA) last released its earnings results on Tuesday, July 27th. The company reported $1.87 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.78 by $0.09. USANA Health Sciences had a net margin of 11.09% and a return on equity of 33.65%. The firm had revenue of $336.84 million during the quarter, compared to analysts’ expectations of $340.20 million. Equities analysts predict that USANA Health Sciences will post 6.31 earnings per share for the current fiscal year.

In related news, insider Robert A. Sinnott sold 1,648 shares of the firm’s stock in a transaction dated Monday, August 16th. The stock was sold at an average price of $95.04, for a total transaction of $156,625.92. Following the sale, the insider now directly owns 1,648 shares in the company, valued at approximately $156,625.92. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director John Turman Fleming sold 300 shares of the firm’s stock in a transaction dated Monday, August 30th. The shares were sold at an average price of $97.26, for a total value of $29,178.00. Following the sale, the director now owns 851 shares of the company’s stock, valued at $82,768.26. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 3,435 shares of company stock valued at $331,837. Corporate insiders own 0.21% of the company’s stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops and manufactures nutritional, personal care and weight-management products. Its product line divided into four categories: Essentials, Optimizers, Foods, Personal Care and Skincare, and All Other. The Essentials Nutritionals category includes vitamin and mineral supplements that provide a foundation of advanced total body nutrition for every age group.

Further Reading: What are the Benefits of Index Funds?

Earnings History and Estimates for USANA Health Sciences (NYSE:USNA)

Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.